For research use only. Not for therapeutic Use.
Etoposide-d3 is a deuterium-labeled form of etoposide, a chemotherapeutic agent used to treat various cancers by inhibiting topoisomerase II, an enzyme critical for DNA replication and repair. The deuterium labeling allows for precise tracking and quantification of etoposide in biological systems through mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy. This labeled compound is crucial for pharmacokinetic studies, helping researchers understand the drug’s metabolism, distribution, and excretion. It also aids in drug development and optimization by providing accurate data on drug interactions and therapeutic efficacy.
Catalog Number | R012249 |
CAS Number | NA |
Synonyms | (5R,5aR,8aR,9S)-9-[[4,6-O-(1R)-Ethylidene-β-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3’,4’:6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one-d3; EPEG;-d3 P 16-213-d3; VePesid-d3; Vepesid J-d3; Zuyeyidal-d3; trans-Etoposi |
Molecular Formula | C₂₉H₂₉D₃O₁₃ |
Purity | ≥95% |
Storage | 3 years -20C powder |
IUPAC Name | (8aR,9R)-5-[[(6R,7S,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-[4-hydroxy-3-methoxy-5-(trideuteriomethoxy)phenyl]-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one |
InChI | InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11?,15?,20?,21-,22+,24-,25+,26?,27-,29+/m1/s1/i2D3 |
InChIKey | VJJPUSNTGOMMGY-WWPGOOPGSA-N |
SMILES | [2H]C([2H])([2H])OC1=C(C(=CC(=C1)[C@H]2[C@@H]3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)O[C@H]6[C@H]([C@H]([C@H]7C(O6)COC(O7)C)O)O)OC)O |